Ardilla Technologies

Ardilla Technologies is a San Francisco-based biotechnology company specializing in high-throughput, high-resolution mapping of the human proteome to drive drug discovery. The company utilizes a proprietary platform that integrates advanced mass spectrometry, chemical biology, and machine learning to identify novel binding sites on proteins. This approach is particularly effective for the discovery of covalent small molecule inhibitors, targeting proteins that have historically been difficult to reach with traditional methods. By systematically exploring the druggable proteome, Ardilla aims to develop a pipeline of precision therapies for oncology, immunology, and other areas of high unmet medical need. The company was founded by industry veterans with backgrounds in digital biology and large-scale data analysis.